Prognostic impact of concordant and discordant cytomorphology of bone marrow involvement in patients with diffuse, large, B-cell lymphoma treated with R-CHOP

Journal of Clinical Pathology

Volumn 66, Issue 5, 2013, Pages 420-425

  Shim, Hyoeun ^a   Oh, Jae Il ^b   Park, Sang Hyuk ^c   Jang, Seongsoo ^c   Park, Chan Jeoung ^c   Huh, Jooryung ^c   Suh, Cheolwon ^c   Chi, Hyun Sook ^c  

^a National Cancer Center   (South Korea)

^b Seoul National University   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ARTICLE; BONE MARROW BIOPSY; BONE MARROW CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL STRUCTURE; CYTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CHILD; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; VINCRISTINE; YOUNG ADULT;

EID: 84876771731     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-201158     Document Type: Article

References (12)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin lymphoma. The non-Hodgkin lymphoma classification project. Blood 1997;89: 3909-18.
2. Campbell J, Seymour JF, Matthews J, et al. The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol 2006;76: 473-80.
3. Chung R, Lai R, Wei P, et al. Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the international prognostic index. Blood 2007; 110: 1278-82. (Pubitemid 47281426)
4. A predictive model for aggressive non-Hodgkin lymphoma. The international non-Hodgkin lymphoma prognostic factors project. N Engl J Med 1993;329: 987-94.
5. Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006;107: 4207-13. (Pubitemid 43801342)
6. Swerdlow SH, Harris NL, et al. eds. World Health Organization classification of tumors of haematopoietic and lymphoid tissues. 4th edn. Lyon, France: IARC Press, 2008.
7. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin disease staging classification. Cancer Res 1971;31: 1860-1.
8. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 1982;5: 649-55. (Pubitemid 13149996)
9. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857-61. (Pubitemid 46348180)
10. Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2011;29: 1452-7.
11. Yoon SO, Suh C, Lee DH, et al. Distribution of lymphoid neoplasms in the Republic of Korea: analysis of 5318 cases according to the World Health Organization classification. Am J Hematol 2010;85: 760-4. 12 2012. http://www.cancer.go.kr/ncic/cics-f/01/012/index.html (accessed 30 Oct 2012)
12. Mathur K, Soutar R. The additional role of bone marrow particle sections ('clot sections') in confirming marrow involvement by multiple myeloma: a single centre study. Int J Lab Hematol 2010;32(1 Pt 1):e179-80.